Vicore Pharma Holding AB (OSTO:VICO) Ending Cash Position : kr336.6 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Vicore Pharma Holding AB Ending Cash Position?

Vicore Pharma Holding AB's Ending Cash Position for the quarter that ended in Sep. 2024 was kr336.6 Mil.

Vicore Pharma Holding AB's quarterly Ending Cash Position declined from Mar. 2024 (kr431.2 Mil) to Jun. 2024 (kr358.7 Mil) and declined from Jun. 2024 (kr358.7 Mil) to Sep. 2024 (kr336.6 Mil).

Vicore Pharma Holding AB's annual Ending Cash Position declined from Dec. 2021 (kr294.2 Mil) to Dec. 2022 (kr256.8 Mil) but then increased from Dec. 2022 (kr256.8 Mil) to Dec. 2023 (kr333.6 Mil).

Vicore Pharma Holding AB Ending Cash Position Historical Data

The historical data trend for Vicore Pharma Holding AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Ending Cash Position Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

187.59

248.62

294.20

256.80

333.62

Vicore Pharma Holding AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Ending Cash Position	Get a 7-Day Free Trial															351.09	333.62	431.17	358.65	336.62

Vicore Pharma Holding AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vicore Pharma Holding AB's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	256.803	+	76.817
	=	333.6

Vicore Pharma Holding AB's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	358.652	+	-22.029
	=	336.6

Vicore Pharma Holding AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

6Y4:Germany

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines